- Home
- BSBK vs STTK Comparison
BSBK vs STTK Comparison
Compare BSBK & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSBK
- STTK
- Stock Information
- Founded
- BSBK 1893
- STTK 2016
- Country
- BSBK United States
- STTK United States
- Employees
- BSBK N/A
- STTK N/A
- Industry
- BSBK Banks
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- BSBK Finance
- STTK Health Care
- Exchange
- BSBK Nasdaq
- STTK Nasdaq
- Market Cap
- BSBK 114.0M
- STTK 112.6M
- IPO Year
- BSBK N/A
- STTK 2020
- Fundamental
- Price
- BSBK $9.29
- STTK $2.35
- Analyst Decision
- BSBK
- STTK Hold
- Analyst Count
- BSBK 0
- STTK 6
- Target Price
- BSBK N/A
- STTK $2.67
- AVG Volume (30 Days)
- BSBK 5.2K
- STTK 548.5K
- Earning Date
- BSBK 10-31-2025
- STTK 11-13-2025
- Dividend Yield
- BSBK N/A
- STTK N/A
- EPS Growth
- BSBK N/A
- STTK N/A
- EPS
- BSBK N/A
- STTK N/A
- Revenue
- BSBK $14,709,306.00
- STTK $2,997,000.00
- Revenue This Year
- BSBK N/A
- STTK N/A
- Revenue Next Year
- BSBK N/A
- STTK N/A
- P/E Ratio
- BSBK N/A
- STTK N/A
- Revenue Growth
- BSBK 16.23
- STTK N/A
- 52 Week Low
- BSBK $6.59
- STTK $0.69
- 52 Week High
- BSBK $9.50
- STTK $2.49
- Technical
- Relative Strength Index (RSI)
- BSBK 56.86
- STTK 66.63
- Support Level
- BSBK $8.76
- STTK $2.13
- Resistance Level
- BSBK $9.38
- STTK $2.49
- Average True Range (ATR)
- BSBK 0.23
- STTK 0.22
- MACD
- BSBK -0.03
- STTK -0.02
- Stochastic Oscillator
- BSBK 71.74
- STTK 80.82
About BSBK Bogota Financial Corp.
Bogota Financial Corp is a New Jersey-based bank. It offers personal and business banking services such as savings, certificates of deposits, online banking, loans, and many more. The Bank generally grants residential, commercial, and consumer loans to, and accepts deposits from customers in New Jersey.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.